Bortezomib
- Generic Name
- Bortezomib
- Brand Names
- Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun
- Drug Type
- Small Molecule
- Chemical Formula
- C19H25BN4O4
- CAS Number
- 179324-69-7
- Unique Ingredient Identifier
- 69G8BD63PP
- Background
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is though...
- Indication
Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.
- Associated Conditions
- Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)
- Associated Therapies
- -
Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2021-07-09
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Abdullah Khan
- Target Recruit Count
- 1
- Registration Number
- NCT04956302
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
- Conditions
- Interventions
- First Posted Date
- 2021-06-11
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 650
- Registration Number
- NCT04923893
- Locations
- 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇺🇸University of Kentucky, Lexington, Kentucky, United States
🇺🇸Norton Cancer Institute, Louisville, Kentucky, United States
Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.
- Conditions
- Interventions
- First Posted Date
- 2021-06-07
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 28
- Registration Number
- NCT04915248
- Locations
- 🇮🇹
A.O. Universitaria Ospedali Riuniti - Ospedale Umberto I Di Ancona, Ancona, Italy
🇮🇹Aviano - IRCCS Centro di Riferimento Oncologico di Aviano - Divisione di Oncologia e dei Tumori immuto-correlati, Aviano, Italy
🇮🇹A.O. Spedali Civili di Brescia - Ematologia, Brescia, Italy
Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease
- Conditions
- Interventions
- First Posted Date
- 2021-06-03
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 1
- Registration Number
- NCT04912427
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 35
- Registration Number
- NCT04892446
- Locations
- 🇺🇸
US Oncology, Inc., IRB, Fairfax, Virginia, United States
🇺🇸US San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸Stanford Cancer Institute, Palo Alto, California, United States
Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients
- Conditions
- Interventions
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2021-12-06
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 50
- Registration Number
- NCT04802356
- Locations
- 🇪🇸
Hospital Gregorio Marañon, Madrid, Comunidad Autónoma De Madrid, Spain
🇪🇸Institut Catala d'Oncologia (ICO) Hospitalet, Hospitalet de Llobregat, Cataluña, Spain
🇪🇸Clinica Universidad Navarra (CUN), Pamplona, Navarra, Spain
Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies
- Conditions
- Interventions
- First Posted Date
- 2021-03-02
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT04776850
DARA RVD For High Risk SMM
- Conditions
- Interventions
- First Posted Date
- 2021-03-01
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Omar Nadeem, MD
- Target Recruit Count
- 61
- Registration Number
- NCT04775550
- Locations
- 🇺🇸
Stamford Hospital, Stamford, Connecticut, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis
- Conditions
- Interventions
- First Posted Date
- 2021-02-15
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Emory University
- Target Recruit Count
- 11
- Registration Number
- NCT04754945
- Locations
- 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).
- Conditions
- Interventions
- First Posted Date
- 2021-02-12
- Last Posted Date
- 2022-09-07
- Lead Sponsor
- Poitiers University Hospital
- Target Recruit Count
- 270
- Registration Number
- NCT04751877
- Locations
- 🇫🇷
CHU Poitiers, Poitiers, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.